Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an International Collaborative Trial

American Journal of Psychiatry

Volumn 154, Issue 4, 1997, Pages 457-465

  Tollefson, Gary D ^a   Beasley, Charles M ^b   Tran, Pierre V ^b   Street, Jamie S ^b   Krueger, John A ^b   Tamura, Roy N ^b   Graffeo, Karin A ^b   Thieme, Martha E ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIZOCILPINE; HALOPERIDOL; OLANZAPINE;

ADULT; AKATHISIA; APPETITE DISORDER; ARTICLE; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; NAUSEA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOIDISM; SCHIZOPHRENIA; TREMOR; VOMITING; XEROSTOMIA;

EID: 0030993030     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.4.457     Document Type: Article

References (39)

1. Andreasen NC: Symptoms, signs, and diagnosis of schizophrenia. Lancer 1995; 346:477-481
2. Carlsson A: Neurocircuitries and neurotransmitter interactions in schizophrenia. Int Clin Psychopharmacol 1995; 10:21-28
3. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
4. Kane JM: Treatment of schizophrenia. Schizophr Bull 1987; 13:133-156
5. Gerlach J, Peacock L: New antipsychotics: the present status. Int Clin Psychopharmacol 1995; 10(suppl 3):39-48
6. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96
7. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW: Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995; 120:67-74
8. Kay SR, Opler LA, Fiszbein A: Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY, Multi-Health Systems, 1986
9. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
10. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
11. Association for Methodology and Documentation in Psychiatry (Arbeltsgemeinschaft fur methodik und dokumentation in der psychiatrie) (AMDP): Das AMDP-system: Manual zur dokumentation psychiatriacher befunde 4. Berlin, Auflage, 1981
12. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
13. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
14. Coding Symbol and Thesaurus for Adverse Event Terminology (COSTART). Rockville, Md, US Department of Health and Human Services, 1990
15. Breier A, Schreiber JL, Dyer J, Pickar D: National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 1991; 48:329-346
16. Crow TJ: The two-syndrome concept: origins and current status. Schizophr Bull 1985; 11:471-486
17. Csernansky JG, Kaplan J, Hollister LE: Problems in classification of schizophrenics as neuroleptic responders and nonresponders. J Nerv Ment Dis 1985; 173:325-331
18. Meltzer HY: Clozapine: is another view valid? (editorial). Am J Psychiatry 1995; 152:821-825
19. Siris SG: Depression and schizophrenia, in Schizophrenia. Edited by Hirsch SR, Weinberger DR. Oxford, England, Blackwell Science, 1995, pp 128-145
20. Casey DE: Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10(suppl 3):105-114
21. Casey DE: Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989; 99(suppl):S47-S53
22. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
23. Kane JM: Schizophrenia. N Engl J Med 1996; 334:34-41
24. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192:481-483
25. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAD Study Group: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123
26. Nemrick-Luecke SK, Snoddy HD, Fuller RW: Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 1994; 55:479-483
27. King DJ: The use of high doses of neuroleptics: the current situation (editorial). Int Clin Psychopharmacol 1994; 9:75-78
28. Beasley CM Jr, Hamilton SH, Crawford AM: Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol (in press)
29. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996; 124: 159-167
30. Stockton ME, Rasmussen K: Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996; 14:97-104
31. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16:1-7
32. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996; 124:148-153
33. Goff DC, Shader RI: Non-neurological side effects of antipsychotic agents, in Schizophrenia. Edited by Hirsch SR, Weinberger DR. Oxford, England, Blackwell Science, 1995, pp 566-586
34. Munyon WH, Salo R, Briones DF: Cytotoxic effects of neuroleptic drugs. Psychopharmacology (Berl) 1987; 91:182-188
35. Dujovne CA, Zimmerman HJ: Cytotoxicity of phenothiazines on chang liver cells as measured by enzyme leakage. Proc Soc Exp Biol Med 1969; 131:583-587
36. Fischer V, Haar JS, Greiner L, Lloyd RV, Mason RP: Possible role of free radical formation in clozapine (Clozaril®-induced agranulocytosis. Mol Pharmacol 1991; 40:2641-2648
37. Uetrecht JP: Metabolism of clozapine by neutrophils: possible implications for clozapine-induced agranulocytosis. Drug Saf 1992; 7(suppl 1):51-56
38. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M: Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149:68-72
39. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multicentre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-726